Does percutaneous closure of patent foramen ovale reduce the risk of recurrent embolic events or death in patients with cryptogenic embolism compared with medical therapy?
Percutaneous closure of a patent foramen ovale does not significantly reduce the risk of recurrent embolic events or death compared to medical therapy for secondary prevention of cryptogenic embolism.
Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant reduction in the risk of recurrent embolic events or death as compared with medical therapy. (Funded by St. Jude Medical; ClinicalTrials.gov number, NCT00166257.).
Meier et al. (Wed,) studied this question.